Media

Oncos Therapeutics recruits Dr Magnus Jaderberg as CMO

Nordic Nanovector To Present Clinical Data from Phase I/II Trial on Betalutin™ at Upcoming American Society of Hematology (ASH) Meeting

Cerenis Therapeutics reports two postivie phase II studies

Oncos Therapeutics granted US and EU Orphan Drug Designation

Aerocrine announce that NICE guidelines support the FeNO measurement in diagnosis and management of asthma

Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001

AEROCRINE AB strengthens its financial position by a rights issue of approximately SEK 445 million

Aerocrine Interim report January – September 2014

Nordic Nanovector and Affibody collaborate on advanced radio-immunotherapies program for Multiple Myeloma

GLIONOVA RECEIVES SEK 5 MILLION GRANT FROM SWEDISH INNOVATION AGENCY VINNOVA